| [1] |
Fox AM, Ciziene D, McLaughlin SH, et al. Electrostatic interactions involving the extreme C terminus of nuclear export factor CRM1 modulate its affinity for cargo[J]. J Biol Chem, 2011, 286(33): 29 325-35.
|
| [2] |
Fornerod M, Ohno M, Yoshida M, et al. CRM1 is an export receptor for leucine-rich nuclear export signals[J]. Cell, 1997, 90 (6): 1051-60.
|
| [3] |
Kutay U, Izaurralde E, Bischoff FR, et al. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex[J]. EMBO J, 1997, 16 (6): 1153-63.
|
| [4] |
Stade K, Ford CS, Guthie C, et al. Exportin 1 (Crm1p) is an essential nuclear export factor[J]. Cell, 1997, 90(6): 1041-50.
|
| [5] |
Strambio-De-Castillia C, Niepel M, Rout MP. The nuclear pore complex: bridging nuclear transport and gene regulation[J]. Nat Rev Mol Cell Biol, 2010, 11(7): 490-501.
|
| [6] |
Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond[J]. Trends Cell Biol, 2007, 17(4): 193-201.
|
| [7] |
Sakakibara K, Saito N, Sato T, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity[J]. Blood, 20 11, 118(14): 3922-31.
|
| [8] |
Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer[J]. Curr Med Chem, 2008, 15 (26): 2648-55.
|
| [9] |
Gao J, Azmi AS, Aboukameel A, et al. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer[J]. Oncotarget, 2014, 5(11): 34 44-54.
|
| [10] |
Levine AJ. p53, the cellular gatekeeper for growth and division[J]. Cell, 1997, 88(3): 323-31.
|
| [11] |
Vogelstein B, Lane D, Levine AJ. Surfing the p53 network[J]. Nature, 2000, 408(6810): 307-10.
|
| [12] |
Vousden KH, Lu X. Live or let die: the cell's response to p53 [J]. Nat Rev Cancer, 2002, 2(8): 594-604.
|
| [13] |
Fridman JS, Lowe SW. Control of apoptosis by p53[J]. Oncogene, 20 03, 22(56): 9030-40.
|
| [14] |
Vurusaner B, Poli G, Basaga H. Tumor suppressor genes and ROS: complex networks of interactions[J]. Free Radic Biol Med, 2012, 52 (1): 7-18.
|
| [15] |
Dotto GP. p21 (WAF1/Cip1): more than a break to the cell cycle? [J] Biochim Biophys Acta, 2000, 1471(1): M43-56.
|
| [16] |
Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis[J]. Mol Cancer Ther, 2002, 1(8): 63 9-49.
|
| [17] |
Li R, Waga S, Hannon GJ, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair[J]. Nature, 1994, 371(6497): 534-7.
|
| [18] |
Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases[J]. Cell, 1993, 75(4): 805-16.
|
| [19] |
Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases[J]. Nature, 1993, 366(6456): 701-4.
|
| [20] |
el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression[J]. Cell, 1993, 75(4): 817-25.
|
| [21] |
Liu R, Wang L, Chen G, et al. FOXP3 up-regulates p21 expression by sitespecific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus[J]. Cancer Res, 2009, 69(6): 22 52-9.
|
| [22] |
Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53?[J]. Biol Cell, 2006, 98(3): 141-52.
|
下载:
